MX391851B - Gliceril 3-hidroxibutiratos para las lesiones cerebrales traumaticas - Google Patents

Gliceril 3-hidroxibutiratos para las lesiones cerebrales traumaticas

Info

Publication number
MX391851B
MX391851B MX2019008269A MX2019008269A MX391851B MX 391851 B MX391851 B MX 391851B MX 2019008269 A MX2019008269 A MX 2019008269A MX 2019008269 A MX2019008269 A MX 2019008269A MX 391851 B MX391851 B MX 391851B
Authority
MX
Mexico
Prior art keywords
brain injury
traumatic brain
hydroxybutyrates
glyceryl
mild
Prior art date
Application number
MX2019008269A
Other languages
English (en)
Spanish (es)
Other versions
MX2019008269A (es
Inventor
Sami Hashim
Original Assignee
Neuroenergy Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroenergy Ventures Inc filed Critical Neuroenergy Ventures Inc
Publication of MX2019008269A publication Critical patent/MX2019008269A/es
Publication of MX391851B publication Critical patent/MX391851B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019008269A 2017-01-12 2017-11-30 Gliceril 3-hidroxibutiratos para las lesiones cerebrales traumaticas MX391851B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/404,396 US9925164B1 (en) 2017-01-12 2017-01-12 Glyceryl 3-hydroxybutyrates for traumatic brain injury
PCT/US2017/063853 WO2018132189A1 (en) 2017-01-12 2017-11-30 Glyceryl 3-hydroxybutyrates for traumatic brain injury

Publications (2)

Publication Number Publication Date
MX2019008269A MX2019008269A (es) 2019-09-13
MX391851B true MX391851B (es) 2025-03-21

Family

ID=61633011

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008269A MX391851B (es) 2017-01-12 2017-11-30 Gliceril 3-hidroxibutiratos para las lesiones cerebrales traumaticas

Country Status (11)

Country Link
US (3) US9925164B1 (enExample)
EP (1) EP3568129A4 (enExample)
JP (1) JP7278593B2 (enExample)
KR (1) KR102443942B1 (enExample)
CN (1) CN110114067A (enExample)
BR (1) BR112019014128A2 (enExample)
CA (1) CA3046355C (enExample)
IL (1) IL267934B2 (enExample)
MX (1) MX391851B (enExample)
MY (1) MY207193A (enExample)
WO (1) WO2018132189A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
CA3021784A1 (en) * 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12091383B2 (en) * 2019-01-17 2024-09-17 Ketolipix Therapeutics Gmbh Method for producing lipids comprising structural units based on glycerides of hydroxycarboxylc acids
JP7235873B2 (ja) * 2019-01-17 2023-03-08 アイオーアイ オレオ ゲーエムベーハー ヒドロキシカルボン酸のグリセリドの製造方法
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
IL288343B2 (en) * 2019-05-30 2024-04-01 Neuroenergy Ventures Inc Glyceryl tris (beta-hydroxybutyrate) and neuronal transient ischemic attacks
WO2020249195A1 (de) * 2019-06-12 2020-12-17 Ioi Oleo Gmbh Verfahren zur herstellung von polyolbasierten estern von ketocarbonsäuren
CN114008015B (zh) * 2019-06-12 2024-02-20 凯托利皮克斯治疗有限责任公司 羟基羧酸多元醇酯、特别是聚甘油酯的制备方法
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
JP2023543110A (ja) * 2020-07-13 2023-10-13 ケトリピックス セラポーティクス ゲーエムベーハー オキソブタノールでエステル化されたポリグリセロールエステルを製造する方法
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
US20240342121A1 (en) * 2021-07-09 2024-10-17 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
IL312317B2 (en) 2021-11-12 2025-04-01 Arxada Ag Polyol-derived compounds
US20250002446A1 (en) 2021-11-26 2025-01-02 Arxada Ag Acetoacetate Based Ketals
WO2023139357A1 (en) * 2022-01-18 2023-07-27 Today Inc. Molecules, nutritional formulations, and methods of providing nutritional support
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
WO2023167989A2 (en) * 2022-03-04 2023-09-07 Guardian Biosciences, LLC Compositions and methods to promote brain health
EP4605371A1 (en) 2022-10-18 2025-08-27 Arxada AG Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
JP4740426B2 (ja) * 1997-03-17 2011-08-03 ビーティージー・インターナショナル・リミテッド 治療用組成物
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
ES2548700T3 (es) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
KR20090003148A (ko) 2006-04-03 2009-01-09 액세라인크 나이와 관련된 기억 손상의 치료를 위한 케톤 생성조성물의 용도
WO2008005818A1 (en) * 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
CA2684213A1 (en) 2007-04-12 2008-10-23 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
JP2009173766A (ja) 2008-01-24 2009-08-06 Ono Kogei Kk 炭素繊維含有コーティング組成物およびその調製方法
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
EA201190115A1 (ru) 2009-01-24 2012-02-28 ФИТОФАРМ ПиЭлСи Лечение расстройств, опосредованных нейротрофическим фактором
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
CA2873057C (en) 2011-05-09 2020-02-25 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
DK2914251T3 (da) 2012-11-05 2019-11-04 Us Health Ketonlegemer til beskyttelse af væv mod beskadigelse som følge af ioniseringsstråling
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
PE20151949A1 (es) 2013-03-19 2016-01-05 Univ South Florida Composiciones y metodos para producir cetosis elevada y sostenida
WO2015034812A2 (en) * 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
CA2973342A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
WO2017011294A1 (en) 2015-07-10 2017-01-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
WO2017165445A1 (en) 2016-03-21 2017-09-28 Csilla Ari D'agostino Administration of exogenous ketone to lower blood glucose
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
CA3021784A1 (en) 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US20180055797A1 (en) 2016-08-31 2018-03-01 KetoneAid Inc. Non-racemic ketone salts for rapid-onset nutritional ketosis and metabolic therapy
CA3036688A1 (en) 2016-09-12 2018-03-15 University Of South Florida Neuroregeneration improved by ketone

Also Published As

Publication number Publication date
KR20190104546A (ko) 2019-09-10
US11638702B2 (en) 2023-05-02
US20180193300A1 (en) 2018-07-12
EP3568129A4 (en) 2020-12-09
US9925164B1 (en) 2018-03-27
IL267934B1 (en) 2024-05-01
IL267934A (en) 2019-09-26
CA3046355A1 (en) 2018-07-19
CA3046355C (en) 2023-08-01
MY207193A (en) 2025-02-05
JP2020504134A (ja) 2020-02-06
MX2019008269A (es) 2019-09-13
IL267934B2 (en) 2024-09-01
US20200297686A1 (en) 2020-09-24
WO2018132189A1 (en) 2018-07-19
CN110114067A (zh) 2019-08-09
KR102443942B1 (ko) 2022-09-15
JP7278593B2 (ja) 2023-05-22
US10736867B2 (en) 2020-08-11
EP3568129A1 (en) 2019-11-20
BR112019014128A2 (pt) 2020-06-16

Similar Documents

Publication Publication Date Title
MX391851B (es) Gliceril 3-hidroxibutiratos para las lesiones cerebrales traumaticas
MX392869B (es) Kit para el tratamiento o alivio de dolor en el sitio de incision despues de un procedimiento quirurgico
WO2015021434A3 (en) Methods and apparatuses for skin treatment using non-thermal tissue ablation
EA201490746A2 (ru) Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга
MY194341A (en) Method of treating a brain tumor
GB2604876B (en) Skin treatment device
PH12017500392A1 (en) Medical treatments based on anamorelin
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
IL313661A (en) Methods of treating brain tumours and neuroblastomas
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
IL271632A (en) Implant for injured nerve tissue prosthetics, method of surgical treatment for injured nerve tissue and use of porous polytetrafluorethylene
IL304628A (en) Treatment of skin disorders
CA207483S (en) Skin treatment device
CA207484S (en) Skin treatment device
ZA202002910B (en) Treatment of skin disorders
EP3585434A4 (en) METHOD OF PHOTOCHEMICAL TREATMENT FOR WOUND HEALING
MX367120B (es) Pinzas para reparación percutánea del tendón de aquiles por mínima invasión.
LT4313114T (lt) Kombinuotas smegenų traumos gydymas
GB202001353D0 (en) Treatment of skin conditions
CA207482S (en) Skin treatment device
GB202116774D0 (en) Treatment of pain
EP3010532A4 (en) Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (mci), early dementia, a-synucleinopathy, traumatic brain injury, cardiomyopathy, eye disease and skin damage
GB202114129D0 (en) Treatment of traumatic brain injury
GB202100566D0 (en) Treatment of brain damage
GB202107701D0 (en) Treatment of traumatic brain injury